Phio Pharmaceuticals — Third Quarter 2026 Earnings Summary

Phio Pharmaceuticals reported a net loss of $4.2 million for the third quarter of 2026, driven primarily by a 159% increase in research and development expenses to $3.0 million as the company advances its PH-762 program. The company successfully completed commercial-scale cGMP manufacturing of PH-762 drug substance and submitted final Phase 1b clinical trial data to the FDA, with a response expected by the end of November 2026. As of September 30, 2026, the company held $10.6 million in cash and cash equivalents, down from $21.0 million at the end of 2025, while planning to initiate a Phase 2b study in the first quarter of 2027.